Eveliqure Biotechnologies GmbH
3 clinical trials · Sponsor
◉ Watch Eveliqure Biotechnologies GmbH
| Record | Firm | Date |
|---|---|---|
| Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old (NCT07049159) | Eveliqure Biotechnologies GmbH | 2025-06-30 |
| ShigETEC Vaccine Study in Bangladesh (NCT05987488) | Eveliqure Biotechnologies GmbH | 2023-11-26 |
| Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults (NCT05409196) | Eveliqure Biotechnologies GmbH | 2020-09-16 |
Track Eveliqure Biotechnologies GmbH automatically
Every clearance here is in the API, with alerts when new ones post.